tiprankstipranks
Trending News
More News >
Ardelyx (ARDX)
NASDAQ:ARDX
Advertisement

Ardelyx (ARDX) AI Stock Analysis

Compare
1,720 Followers

Top Page

ARDX

Ardelyx

(NASDAQ:ARDX)

Rating:63Neutral
Price Target:
$4.50
▲(6.13%Upside)
Ardelyx's overall score reflects strong revenue growth and strategic financial moves, such as the loan amendment, against the backdrop of profitability and cash flow challenges. Positive technical indicators provide market support, while valuation concerns highlight the need for improved profitability.
Positive Factors
Market Potential
$1B peak Ibsrela net sales guidance looks achievable and possibly conservative, requiring less than 10% of the current annual prescription volume.
Product Differentiation
Ibsrela remains the only non-secretagogue on the market, likely making it the preferred second-line agent and appealing to a large number of refractory patients.
Negative Factors
Medicare Access Challenges
A positive appeals decision could restore Part D for Xphozah and add back a large growth driver for the stock.
Revenue Performance
A small sequential retracement in overall Xphozah revenue is expected from the first quarter to the second quarter, with growth likely returning in the third quarter.

Ardelyx (ARDX) vs. SPDR S&P 500 ETF (SPY)

Ardelyx Business Overview & Revenue Model

Company DescriptionArdelyx, Inc. (ARDX) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to improve treatment for people with cardiorenal diseases. The company primarily operates in the healthcare sector with a focus on pharmaceuticals, and its core product offerings include tenapanor, a first-in-class medicine for the treatment of irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in patients with chronic kidney disease on dialysis.
How the Company Makes MoneyArdelyx generates revenue through the commercialization of its pharmaceutical products, primarily tenapanor. The company earns money by selling its approved drug to healthcare providers and through partnerships with other pharmaceutical companies for the distribution and co-development of its treatments. Additionally, Ardelyx may receive milestone payments and royalties from licensing agreements and collaborations with other companies in the pharmaceutical industry. The company's revenue is significantly influenced by its ability to successfully market its products and expand its reach in the healthcare market.

Ardelyx Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q1-2025)
|
% Change Since: -22.49%|
Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment Neutral
The earnings call highlights significant revenue growth and strategic progress with IBSRELA and XPHOZAH. However, challenges such as market contractions, Medicare disruptions, and increased expenses were noted. The company's strong cash position and milestone achievement in China provide additional positives.
Q1-2025 Updates
Positive Updates
Significant Revenue Growth
Ardelyx reported a 61% increase in revenue, totaling $74 million compared to the same period last year.
IBSRELA's Strong Performance
IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by strong prescription demand and effective commercial execution.
XPHOZAH's Growth
XPHOZAH revenue grew by 30% compared to last year, with successful patient access across Medicare and non-Medicare segments.
Financial Milestone
Ardelyx earned a $5 million milestone from their partner in China following the approval of Tenapanor for hyperphosphatemia.
Strong Cash Position
As of March 31, 2025, Ardelyx had $214 million in cash, cash equivalents, and short-term investments.
Negative Updates
IBSC Market Contraction
The IBSC market traditionally contracts in the first quarter, impacting sales figures despite strong prescription demand for IBSRELA.
Medicare Part D Disruption
The elimination of Medicare Part D coverage for phosphate-lowering therapies caused significant disruption in the dialysis market.
Increased Expenses
Research and development expenses rose to $14.9 million from $10.6 million, and SG&A expenses increased significantly, impacting net loss.
Net Loss Increase
Ardelyx reported a net loss of $41.1 million, up from $26.5 million in the same period last year.
Company Guidance
During the first quarter of 2025, Ardelyx reported a significant 61% year-over-year revenue growth, reaching $74 million. This growth was driven by robust performances from their commercial products, IBSRELA and XPHOZAH. IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by a strong prescription demand and strategic efforts to enhance prescriber adoption and patient access. The company reaffirmed its 2025 guidance of $240 million to $250 million in net sales and anticipates peak annual net sales revenue exceeding $1 billion for IBSRELA. XPHOZAH, despite market disruptions, grew by 30% from the previous year, excluding adjustments, totaling $23.4 million in net sales revenue. Ardelyx remains confident in achieving a peak sales target of $750 million for XPHOZAH, focusing on non-Medicare segments amid ongoing Medicare Part D changes. The company reported a net loss of $41.1 million and maintained a strong cash position of $214 million as of March 31, 2025.

Ardelyx Financial Statement Overview

Summary
Ardelyx demonstrates promising revenue growth, but faces significant profitability and cash flow challenges. Despite a stable balance sheet, negative net profit margins and cash flow issues hinder overall financial health.
Income Statement
65
Positive
Ardelyx has shown a strong revenue growth trajectory with substantial increases in total revenue over recent periods. Gross profit margin is healthy, but the company is still facing challenges with profitability as reflected by a negative net profit margin. The EBIT and EBITDA margins are also negative, indicating operational challenges and cost management issues.
Balance Sheet
55
Neutral
The company maintains a moderate debt-to-equity ratio, indicating a balanced approach in leveraging financing through debt. However, the return on equity remains negative due to consistent net losses, indicating the need for improved profitability to enhance shareholder returns. The equity ratio suggests a stable capital structure, but overall asset utilization needs improvement for better financial health.
Cash Flow
60
Neutral
Despite negative operating cash flows, Ardelyx has managed to maintain adequate liquidity through financing activities. However, the free cash flow remains negative, indicating challenges in generating surplus cash from operations. The ratios of operating and free cash flow to net income are unfavorable, highlighting persistent cash flow management difficulties.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue333.62M124.46M52.16M10.10M7.57M
Gross Profit283.06M106.66M48.04M9.10M7.43M
EBITDA-16.71M-55.35M-60.98M-150.85M-85.24M
Net Income-39.14M-66.07M-67.21M-158.16M-94.31M
Balance Sheet
Total Assets435.75M297.58M190.07M149.91M201.56M
Cash, Cash Equivalents and Short-Term Investments250.10M184.30M123.91M116.69M186.48M
Total Debt153.44M55.98M36.46M45.50M53.32M
Total Liabilities262.46M130.76M91.74M67.30M75.45M
Stockholders Equity173.29M166.82M98.33M82.62M126.11M
Cash Flow
Free Cash Flow-45.82M-90.06M-70.10M-154.42M-81.76M
Operating Cash Flow-44.81M-89.72M-70.04M-152.55M-81.44M
Investing Cash Flow-18.32M-131.25M18.41M50.95M-31.44M
Financing Cash Flow106.59M146.29M75.34M83.00M22.78M

Ardelyx Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4.24
Price Trends
50DMA
4.04
Positive
100DMA
4.37
Negative
200DMA
4.88
Negative
Market Momentum
MACD
0.06
Positive
RSI
49.08
Neutral
STOCH
13.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDX, the sentiment is Negative. The current price of 4.24 is below the 20-day moving average (MA) of 4.42, above the 50-day MA of 4.04, and below the 200-day MA of 4.88, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 49.08 is Neutral, neither overbought nor oversold. The STOCH value of 13.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARDX.

Ardelyx Risk Analysis

Ardelyx disclosed 52 risk factors in its most recent earnings report. Ardelyx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ardelyx Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$1.06B33.3316.62%6.85%-67.67%
78
Outperform
$1.21B32.7717.33%25.59%
63
Neutral
$1.01B-36.26%127.33%21.31%
55
Neutral
$1.60B-188.03%-11.42%0.26%
53
Neutral
$1.84B-57.19%-0.33%-3.59%
52
Neutral
kr5.49B9.89-63.86%2.02%27.11%26.73%
49
Neutral
$1.46B-23.20%24.49%5.14%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ARDX
Ardelyx
4.24
-1.81
-29.92%
CLDX
Celldex
21.98
-12.80
-36.80%
MDXG
MiMedx Group
7.19
0.73
11.30%
OCUL
Ocular Therapeutix
11.58
3.80
48.84%
AUPH
Aurinia Pharmaceuticals
9.24
3.74
68.00%
LQDA
Liquidia Technologies
18.69
7.46
66.43%

Ardelyx Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Ardelyx Secures $50 Million Loan Amendment
Positive
Jul 3, 2025

On June 30, 2025, Ardelyx, Inc. amended its Loan and Security Agreement, initially dated February 23, 2022, with SLR Investment Corp. and other lenders. The Fifth Amendment allowed Ardelyx to immediately draw $50 million and provided options for additional loans totaling $100 million. The loans have specific interest rates and maturity dates, with interest-only payments allowed until maturity. The amendment impacts Ardelyx’s financial strategy by securing significant funding options for future operations.

The most recent analyst rating on (ARDX) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Ardelyx stock, see the ARDX Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Ardelyx Stockholders Approve Equity Plan Amendment
Neutral
Jun 18, 2025

On June 18, 2025, Ardelyx, Inc. held its Annual Meeting where stockholders approved an amendment to the 2014 Equity Incentive Award Plan. This amendment, initially approved by the Board on April 28, 2025, aims to enhance the company’s equity compensation framework. The meeting also saw the election of Class II directors, approval of the Say-On-Pay proposal, and ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ARDX) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Ardelyx stock, see the ARDX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025